Cargando…

From hormone replacement therapy to regenerative scaffolds: A review of current and novel primary hypothyroidism therapeutics

Primary hypothyroidism severely impacts the quality of life of patients through a decrease in the production of the thyroid hormones T3 and T4, leading to symptoms affecting cardiovascular, neurological, cognitive, and metabolic function. The incidence rate of primary hypothyroidism is expected to i...

Descripción completa

Detalles Bibliográficos
Autores principales: Heim, Maria, Nixon, Ian J., Emmerson, Elaine, Callanan, Anthony
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9581390/
https://www.ncbi.nlm.nih.gov/pubmed/36277721
http://dx.doi.org/10.3389/fendo.2022.997288
_version_ 1784812615016382464
author Heim, Maria
Nixon, Ian J.
Emmerson, Elaine
Callanan, Anthony
author_facet Heim, Maria
Nixon, Ian J.
Emmerson, Elaine
Callanan, Anthony
author_sort Heim, Maria
collection PubMed
description Primary hypothyroidism severely impacts the quality of life of patients through a decrease in the production of the thyroid hormones T3 and T4, leading to symptoms affecting cardiovascular, neurological, cognitive, and metabolic function. The incidence rate of primary hypothyroidism is expected to increase in the near future, partially due to increasing survival of patients that have undergone radiotherapy for head and neck cancer, which induces this disease in over half of those treated. The current standard of care encompasses thyroid hormone replacement therapy, traditionally in the form of synthetic T4. However, there is mounting evidence that this is unable to restore thyroid hormone signaling in all tissues due to often persistent symptoms. Additional complications are also present in the form of dosage difficulties, extensive drug interactions and poor patience compliance. The alternative therapeutic approach employed in the past is combination therapy, which consists of administration of both T3 and T4, either synthetic or in the form of desiccated thyroid extract. Here, issues are present regarding the lack of regulation concerning formulation and lack of data regarding safety and efficacy of these treatment methods. Tissue engineering and regenerative medicine have been applied in conjunction with each other to restore function of various tissues. Recently, these techniques have been adapted for thyroid tissue, primarily through the fabrication of regenerative scaffolds. Those currently under investigation are composed of either biopolymers or native decellularized extracellular matrix (dECM) in conjunction with either primary thyrocytes or stem cells which have undergone directed thyroid differentiation. Multiple of these scaffolds have successfully restored an athyroid phenotype in vivo. However, further work is needed until clinical translation can be achieved. This is proposed in the form of exploration and combination of materials used to fabricate these scaffolds, the addition of peptides which can aid restoration of tissue homeostasis and additional in vivo experimentation providing data on safety and efficacy of these implants.
format Online
Article
Text
id pubmed-9581390
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95813902022-10-20 From hormone replacement therapy to regenerative scaffolds: A review of current and novel primary hypothyroidism therapeutics Heim, Maria Nixon, Ian J. Emmerson, Elaine Callanan, Anthony Front Endocrinol (Lausanne) Endocrinology Primary hypothyroidism severely impacts the quality of life of patients through a decrease in the production of the thyroid hormones T3 and T4, leading to symptoms affecting cardiovascular, neurological, cognitive, and metabolic function. The incidence rate of primary hypothyroidism is expected to increase in the near future, partially due to increasing survival of patients that have undergone radiotherapy for head and neck cancer, which induces this disease in over half of those treated. The current standard of care encompasses thyroid hormone replacement therapy, traditionally in the form of synthetic T4. However, there is mounting evidence that this is unable to restore thyroid hormone signaling in all tissues due to often persistent symptoms. Additional complications are also present in the form of dosage difficulties, extensive drug interactions and poor patience compliance. The alternative therapeutic approach employed in the past is combination therapy, which consists of administration of both T3 and T4, either synthetic or in the form of desiccated thyroid extract. Here, issues are present regarding the lack of regulation concerning formulation and lack of data regarding safety and efficacy of these treatment methods. Tissue engineering and regenerative medicine have been applied in conjunction with each other to restore function of various tissues. Recently, these techniques have been adapted for thyroid tissue, primarily through the fabrication of regenerative scaffolds. Those currently under investigation are composed of either biopolymers or native decellularized extracellular matrix (dECM) in conjunction with either primary thyrocytes or stem cells which have undergone directed thyroid differentiation. Multiple of these scaffolds have successfully restored an athyroid phenotype in vivo. However, further work is needed until clinical translation can be achieved. This is proposed in the form of exploration and combination of materials used to fabricate these scaffolds, the addition of peptides which can aid restoration of tissue homeostasis and additional in vivo experimentation providing data on safety and efficacy of these implants. Frontiers Media S.A. 2022-10-05 /pmc/articles/PMC9581390/ /pubmed/36277721 http://dx.doi.org/10.3389/fendo.2022.997288 Text en Copyright © 2022 Heim, Nixon, Emmerson and Callanan https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Heim, Maria
Nixon, Ian J.
Emmerson, Elaine
Callanan, Anthony
From hormone replacement therapy to regenerative scaffolds: A review of current and novel primary hypothyroidism therapeutics
title From hormone replacement therapy to regenerative scaffolds: A review of current and novel primary hypothyroidism therapeutics
title_full From hormone replacement therapy to regenerative scaffolds: A review of current and novel primary hypothyroidism therapeutics
title_fullStr From hormone replacement therapy to regenerative scaffolds: A review of current and novel primary hypothyroidism therapeutics
title_full_unstemmed From hormone replacement therapy to regenerative scaffolds: A review of current and novel primary hypothyroidism therapeutics
title_short From hormone replacement therapy to regenerative scaffolds: A review of current and novel primary hypothyroidism therapeutics
title_sort from hormone replacement therapy to regenerative scaffolds: a review of current and novel primary hypothyroidism therapeutics
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9581390/
https://www.ncbi.nlm.nih.gov/pubmed/36277721
http://dx.doi.org/10.3389/fendo.2022.997288
work_keys_str_mv AT heimmaria fromhormonereplacementtherapytoregenerativescaffoldsareviewofcurrentandnovelprimaryhypothyroidismtherapeutics
AT nixonianj fromhormonereplacementtherapytoregenerativescaffoldsareviewofcurrentandnovelprimaryhypothyroidismtherapeutics
AT emmersonelaine fromhormonereplacementtherapytoregenerativescaffoldsareviewofcurrentandnovelprimaryhypothyroidismtherapeutics
AT callanananthony fromhormonereplacementtherapytoregenerativescaffoldsareviewofcurrentandnovelprimaryhypothyroidismtherapeutics